--- title: "CX11 | PepTracker Pro" description: "CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "CX11", "description": "CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results.", "url": "https://peptrackerpro.com/peptides/cx11", "lastReviewed": "2026-07-15", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "CX11", "item": "https://peptrackerpro.com/peptides/cx11" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People interested in oral weight-loss medications that avoid injections?", "acceptedAnswer": { "@type": "Answer", "text": "CX11 is a research peptide studied in preclinical models. CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results." } }, { "@type": "Question", "name": "Those following the emerging oral small-molecule GLP-1 competitive landscape?", "acceptedAnswer": { "@type": "Answer", "text": "CX11 is a research peptide studied in preclinical models. CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results." } }, { "@type": "Question", "name": "Individuals comparing tolerability and liver-safety profiles across oral GLP-1 candidates?", "acceptedAnswer": { "@type": "Answer", "text": "CX11 is a research peptide studied in preclinical models. CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results." } } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Peptides](/peptides)/ CX11 **Research-only content.** This page is for educational purposes and does not constitute medical advice. [Read full disclaimer →](/research-disclaimer) # CX11 Medium Evidence CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results. Aliases CX11 +4 more Evidence Medium Evidence Last Updated 2026-07-15 Reading Time 4 min ## Table of Contents 1. [What It Is](#what-it-is) 2. [Regulatory Status](#regulatory-status) 3. [Why Researchers Study It](#why-researchers-study) 4. [Proposed Mechanisms](#proposed-mechanisms) 5. [Evidence Snapshot](#evidence-snapshot) 6. [Commonly Discussed Benefits](#benefits) 7. [Safety & Cautions](#safety) 8. [Comparisons](#comparisons) 9. [Calculator Tools](#calculator) 10. [Citations](#citations) ## What It Is CX11 is an investigational once-daily oral small-molecule (non-peptide) GLP-1 receptor agonist being developed for obesity, overweight, and type 2 diabetes. It was discovered by Vincentage Pharma Co., Ltd. (China), with global ex-China rights acquired by Corxel Pharmaceuticals in December 2024. Like orforglipron, danuglipron, and aleniglipron, CX11 belongs to the emerging class of small-molecule GLP-1 agonists engineered to reproduce the appetite- and glucose-regulating effects of injectable incretin drugs (semaglutide, tirzepatide) in a scalable, room-temperature-stable pill that avoids cold-chain storage and once-weekly injections. On June 23, 2026, Corxel reported positive top-line results from a U.S. Phase 2 trial (NCT07011797) that enrolled 246 adults with obesity (BMI >= 30) or overweight (BMI 27 to <30 with at least one weight-related comorbidity), randomized 1:1:1:1:1 to CX11 120 mg, 160 mg, 200 mg (slow titration), 200 mg (fast titration), or placebo once daily for 36 weeks. CX11 met its primary endpoints, achieving up to 11.5% weight loss at 36 weeks with weight reduction continuing at a consistent rate and no evidence of a slowing (plateauing) trajectory - a pattern suggesting further loss with longer treatment. The tolerability profile was a headline feature: nausea occurred in 33-34% of participants, vomiting in just 12-16%, diarrhea in 4-12%, and constipation in 2-12%, with no severe GI events and GI adverse events concentrated during dose escalation before subsiding during maintenance. The overall discontinuation rate due to GI adverse events was low at 5.0%. Across more than 1,500 participants studied to date (including the China program), no hepatic safety signal has been identified - an important point given that hepatotoxicity concerns ended Pfizer's first oral GLP-1 candidate lotiglipron and complicated twice-daily danuglipron. The U.S. Phase 2 data were described as consistent with the competitive profile established in Vincentage's positive China Phase 3 obesity program. Corxel plans to advance CX11 into pivotal global Phase 3 studies in weight management, and is also developing CX12, an internally discovered oral small-molecule amylin receptor agonist, plus JX10, a thrombolytic for acute ischemic stroke. Also known as: CX11, CX-11, Corxel oral GLP-1, Vincentage oral GLP-1 receptor agonist, oral small-molecule GLP-1 RA (Corxel/Vincentage) ## Regulatory Status Investigational - not approved U.S. Phase 2 trial (NCT07011797) met its primary endpoints in June 2026 with up to 11.5% weight loss at 36 weeks. Partner Vincentage previously reported positive China obesity Phase 3 results. Corxel plans to initiate pivotal global Phase 3 studies in weight management. Not approved for any indication. Effective: June 2026 [View FDA Source](https://www.biospace.com/press-releases/corxel-pharmaceuticals-reports-positive-top-line-results-from-phase-2-trial-of-cx11-in-obese-and-overweight-u-s-adults) ## Why Researchers Study It CX11 is part of the wave of oral non-peptide GLP-1 agonists that could dramatically widen access to incretin-based obesity therapy by removing the injection, cold-chain, and manufacturing-scale barriers of peptide drugs. Its Phase 2 profile is of particular interest because it pairs double-digit weight loss with a markedly low vomiting rate and a clean hepatic safety record across >1,500 participants - the two attributes (tolerability and liver safety) that have most often tripped up earlier oral GLP-1 candidates. ## Proposed Mechanisms - Small-molecule agonism of the GLP-1 receptor, reducing appetite and caloric intake - Delays gastric emptying to promote satiety and reduce food intake - Enhances glucose-dependent insulin secretion, supporting glycemic control - Non-peptide structure allows once-daily oral dosing without the absorption enhancers or strict fasting requirements of peptide-based oral GLP-1s ## Evidence Snapshot Medium Evidence Low Medium High Study Type Model Outcome Link Phase 2 (U.S., NCT07011797) - randomized, double-blind, placebo-controlled 246 adults with obesity (BMI >= 30) or overweight (BMI 27 to <30 + comorbidity) - 36 weeks, once-daily oral Met primary endpoints: up to 11.5% weight loss at 36 weeks with no plateau; low GI burden (nausea 33-34%, vomiting 12-16%, diarrhea 4-12%, constipation 2-12%); 5.0% discontinuation due to GI AEs; no hepatic safety signal [Source](https://www.biospace.com/press-releases/corxel-pharmaceuticals-reports-positive-top-line-results-from-phase-2-trial-of-cx11-in-obese-and-overweight-u-s-adults) Phase 3 (China, Vincentage Pharma) Adults with obesity/overweight - oral CX11 Positive obesity Phase 3 results reported by partner Vincentage; described as establishing the competitive profile confirmed in the U.S. Phase 2 trial [Source](https://www.biospace.com/press-releases/corxel-pharmaceuticals-reports-positive-top-line-results-from-phase-2-trial-of-cx11-in-obese-and-overweight-u-s-adults) ## Commonly Discussed Benefits [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[Glycemic Control](/benefits/glycemic-control) Researching CX11 ? Track it, set reminders, and keep notes in the free app. [Track in App](https://app.peptrackerpro.com/?add=cx11) ## Safety & Cautions - Investigational - not approved for any indication; Phase 2 (U.S.) and Phase 3 (China) completed, global Phase 3 not yet started - Top-line results only; full peer-reviewed data and detailed dose-response not yet published - GI adverse events (nausea, vomiting, diarrhea, constipation) common, mainly during dose escalation - China Phase 3 results reported by the partner rather than in a peer-reviewed journal at time of writing; cross-trial comparisons with orforglipron, aleniglipron, and oral semaglutide have significant limitations - Long-term safety, durability of weight loss, and cardiovascular outcomes not yet established ## Comparisons See how CX11 compares to related peptides: [CX11 vs Aleniglipron](/compare/cx11-vs-aleniglipron) [CX11 vs Conveglipron](/compare/cx11-vs-conveglipron) [CX11 vs Danuglipron](/compare/cx11-vs-danuglipron) [CX11 vs Ecnoglutide](/compare/cx11-vs-ecnoglutide) [CX11 vs Orforglipron](/compare/cx11-vs-orforglipron) [CX11 vs Semaglutide](/compare/cx11-vs-semaglutide) ## Calculator Tools Use our research tools to explore dosing and reconstitution data: [Reconstitution Calculator](/calculators) ## Citations 1. \[1\] Corxel Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Trial of CX11 in Obese and Overweight U.S. Adults - BioSpace (June 23, 2026) [PubMed](https://www.biospace.com/press-releases/corxel-pharmaceuticals-reports-positive-top-line-results-from-phase-2-trial-of-cx11-in-obese-and-overweight-u-s-adults) 2. \[2\] Corxel to advance oral obesity drug to Phase III trials - Clinical Trials Arena (2026) [PubMed](https://www.clinicaltrialsarena.com/news/corxel-to-advance-oral-obesity-drug-to-phase-iii-trials/) 3. \[3\] CX11 Shows Weight Loss in Phase 2 Obesity Trial, Corxel Reports - HCPLive (2026) [PubMed](https://www.hcplive.com/view/cx11-shows-weight-loss-in-phase-2-obesity-trial-corxel-reports) 4. \[4\] Corxel gears up for global pivotal push after oral GLP-1 posts 'competitive' phase 2 results - Fierce Biotech (2026) [PubMed](https://www.fiercebiotech.com/biotech/corxel-gears-global-pivotal-push-after-oral-glp-1-posts-competitive-ph-2-results) ### Keep researching in the app - Log CX11 to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack [Open PepTracker Pro Free](https://app.peptrackerpro.com/?add=cx11) [Browse more peptides](/peptides) ## Related Peptides ### Aleniglipron Medium Evidence An oral non-peptide small-molecule GLP-1 receptor agonist achieving 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II, with Phase 3 on track for Q3 2026 after positive FDA end-of-Phase 2 feedback. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/aleniglipron) [\+ Compare](/compare?select=aleniglipron)[](https://app.peptrackerpro.com/?add=aleniglipron) ### Conveglipron Low Evidence An oral, once-daily small-molecule GLP-1 receptor agonist (developmental code HDM1002) from Huadong Medicine, in clinical trials for obesity and type 2 diabetes — part of the next wave of GLP-1 'pills' competing with orforglipron. [Fat Loss](/benefits/fat-loss)[appetite-control](/benefits/appetite-control)[Metabolism](/benefits/metabolism) [View Details](/peptides/conveglipron) [\+ Compare](/compare?select=conveglipron)[](https://app.peptrackerpro.com/?add=conveglipron) ### Danuglipron Medium Evidence An oral small-molecule GLP-1 receptor agonist discontinued by Pfizer in 2026 after a potential drug-induced liver injury signal, despite showing meaningful weight loss in Phase 2b. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism) [View Details](/peptides/danuglipron) [\+ Compare](/compare?select=danuglipron)[](https://app.peptrackerpro.com/?add=danuglipron) ### Ecnoglutide High Evidence A cAMP signaling-biased GLP-1 receptor agonist approved in China for chronic weight management, with Phase 3 data showing up to 15.4% weight loss. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism) [View Details](/peptides/ecnoglutide) [\+ Compare](/compare?select=ecnoglutide)[](https://app.peptrackerpro.com/?add=ecnoglutide) ### Orforglipron High Evidence The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/orforglipron) [\+ Compare](/compare?select=orforglipron)[](https://app.peptrackerpro.com/?add=orforglipron) ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+3 more [View Details](/peptides/semaglutide) [\+ Compare](/compare?select=semaglutide)[](https://app.peptrackerpro.com/?add=semaglutide) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.